Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
NANOBIOTIX (NASDAQ: NBTX) announced its annual Combined Shareholders Meeting will be held online on April 28, 2021, at 5pm CET with no physical attendance due to COVID-19 measures. Shareholders can vote via postal voting or proxy, with details available in the convene notice published in the Bulletin des Annonces Légales Obligatoires. Written questions must be submitted by April 22, 2021. The meeting format may change according to health regulations. NANOBIOTIX focuses on physics-based cancer treatment innovations and holds numerous patents in nanomedicine.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company, announced the filing of its universal registration document and annual report for the fiscal year ended December 31, 2020. These documents, which include the annual financial report and management report, are available on the company's website and the regulatory authorities' sites. Nanobiotix is pioneering physics-based approaches in oncology and has market authorization for its lead product, NBTXR3, in Europe for soft tissue sarcoma. The company is headquartered in Paris and operates subsidiaries in Spain and Germany.
Nanobiotix (NANO, NBTX) reported its fiscal year 2020 results, highlighting stable revenues of €2.5M, primarily from research tax credit and collaboration agreements. Net loss decreased to €33.6M from €50.9M in 2019. R&D expenses fell to €24.3M due to cost-control measures. The company achieved significant milestones, including FDA fast track designation for NBTXR3 in head and neck cancer and progressing towards global phase III trials. Successful IPO raised €93.5M, enhancing financial stability as they aim to advance cancer treatment solutions.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced the termination of its License and Collaboration agreement with PharmaEngine, originally established in August 2012. The decision follows disputes over the development strategy of NBTXR3 in the Asia-Pacific region. Nanobiotix retains all rights for NBTXR3, with potential payments to PharmaEngine not exceeding $5 million and royalties on sales for up to 10 years. This shift allows Nanobiotix to explore new opportunities, including evaluating the region for future clinical trials.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a clinical-stage biotechnology company, announced CEO Laurent Levy's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The event will feature on-demand sessions and opportunities for one-on-one meetings with investors. NANOBIOTIX focuses on innovative cancer treatments, highlighted by its lead product NBTXR3, a radioenhancer designed to improve radiotherapy efficacy while reducing toxicity. More details, including the corporate presentation, can be found on their website.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced promising preclinical findings for its radioenhancer NBTXR3 at the AACR Virtual Special Conference. This unique treatment leverages hafnium oxide nanoparticles to enhance radiotherapy's effects without harming adjacent healthy tissue. The study demonstrated that NBTXR3 combined with anti-PD-1 and immune checkpoint inhibitors significantly improved tumor control and survival in resistant mouse models. The company's approach aims to broaden treatment options across various cancers, suggesting potential advancements in cancer therapy.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reported a full year 2020 revenue of approximately €50K, down from €68K in 2019. The lack of Q4 revenues was due to a credit note issued after annual adjustments. As of December 31, 2020, cash and cash equivalents totaled €119.2M, bolstered by a successful IPO generating €93.5M in gross proceeds. Key events include the initiation of multiple clinical trials for NBTXR3 and collaboration agreements, including a partnership with Sanofi. The company expects its current funds to support operations through mid-2023.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reports the first patient has been injected in a Phase I study of NBTXR3, designed for esophageal cancer treatment alongside radiotherapy and chemotherapy at MD Anderson Cancer Center. This trial explores the drug's potential to enhance existing cancer therapies. Esophageal cancer is a significant health concern, with over 508,000 global deaths in 2018. The study aims to establish a recommended dose and monitor toxicity, enrolling up to 24 subjects over 24 months.
Nanobiotix (Paris:NANO) (NASDAQ:NBTX) announced a collaboration through its subsidiary Curadigm to advance gene therapy development using its proprietary Nanoprimer technology. The one-year agreement with a pharmaceutical company aims to improve treatment outcomes by enhancing the bioavailability of therapeutics and minimizing hepatic toxicity. The Nanoprimer technology helps prevent rapid clearance in the liver, allowing more drugs to accumulate in target tissues. This partnership is expected to foster new opportunities, particularly with RNA-based therapies, bolstering Curadigm's pipeline.
NANOBIOTIX (NASDAQ:NBTX, Euronext:NANO) has announced positive results from the phase Ib part of a phase Ib/II study evaluating NBTXR3 combined with concurrent chemotherapy for treating locally advanced rectal cancer. Conducted in Taiwan, the study involved 20 patients and highlighted a favorable safety profile, with no serious adverse events linked to NBTXR3. Over 70% of participants showed tumor response post-treatment, and 90% underwent surgery, with 17.6% achieving complete pathological response. The study sets the recommended phase II dose at 22% of tumor volume.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
